Cargando…

Preclinical development of CD126 CAR-T cells with broad antitumor activity

Chimeric antigen receptor T (CAR-T) cell therapy is a transformative approach to cancer eradication. CAR-T is expensive partly due to the restricted use of each CAR construct for specific tumors. Thus, a CAR construct with broad antitumor activity can be advantageous. We identified that CD126 is exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Ameet K., Kemler, Iris, Dingli, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791061/ https://www.ncbi.nlm.nih.gov/pubmed/33414408 http://dx.doi.org/10.1038/s41408-020-00405-z

Ejemplares similares

Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models
por: Csaplár, Marianna, et al.
Publicado: (2021)

Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
por: Moghadam, Ebrahim Rahmani, et al.
Publicado: (2020)

Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
por: Lin, Regina J., et al.
Publicado: (2023)

T-bet promotes potent antitumor activity of CD4(+) CAR T cells
por: Gacerez, Albert T, et al.
Publicado: (2018)

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023)

Oncolytic virotherapy – in vivo veritas
por: Kemler, Iris, et al.
Publicado: (2018)

In Vivo Imaging of Oncolytic Measles Virus Propagation with Single-Cell Resolution
por: Kemler, Iris, et al.
Publicado: (2018)

Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
por: Cheng, Jiali, et al.
Publicado: (2023)

Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia
por: Wu, Gongqiang, et al.
Publicado: (2023)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
por: Zhang, Shangkun, et al.
Publicado: (2022)

Design and preclinical testing of an anti‐CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
por: Tigu, Adrian Bogdan, et al.
Publicado: (2023)

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells
por: Liao, Chan, et al.
Publicado: (2023)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19
por: Wen, Hairuo, et al.
Publicado: (2021)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
por: Zhou, Wenping, et al.
Publicado: (2023)

Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2022)

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
por: Rodriguez-Marquez, Paula, et al.
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
por: Lin, Liang, et al.
Publicado: (2020)

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019)

Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays
por: Wang, Xiao, et al.
Publicado: (2019)

CD103(+) cDC1 and endogenous CD8(+) T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
por: Kuhn, Nicholas F., et al.
Publicado: (2020)

Diacylglycerol Kinase ζ Limits Cytokine-dependent Expansion of CD8(+) T Cells with Broad Antitumor Capacity
por: Andrada, Elena, et al.
Publicado: (2017)

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
por: Nishimoto, Kevin P, et al.
Publicado: (2022)

Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies
por: Lee, Boon kiat, et al.
Publicado: (2022)

Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4(+) CAR T-cell antitumor activity
por: Boulch, Morgane, et al.
Publicado: (2023)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Preclinical Evaluation of Novel Triphenylphosphonium Salts with Broad-Spectrum Activity
por: Millard, Melissa, et al.
Publicado: (2010)

Incorporation of functional elements enhances the antitumor capacity of CAR T cells
por: Qin, Le, et al.
Publicado: (2017)

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
por: Si, Xiaohui, et al.
Publicado: (2022)

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
por: Li, Hongwen, et al.
Publicado: (2022)

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
por: Dickinson, Michael J., et al.
Publicado: (2023)

CD36 Participates in PrP(106–126)-Induced Activation of Microglia
por: Kouadir, Mohammed, et al.
Publicado: (2012)

Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
por: Chung, Suyoun, et al.
Publicado: (2016)

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
por: Dicitore, Alessandra, et al.
Publicado: (2023)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_65nk327t9s5clp1h8ijjkk0h9s